Aktis Oncology Kickstarts 2026 with $318M IPO to Advance Radiopharmaceutical Cancer Treatments
Aktis Oncology’s public offering is set to strengthen its position in the radiopharmaceutical sector. The company’s novel approach with miniprotein-based radioconjugates promises potential benefits over existing targeted radiation therapies. Additionally, Aktis has established a discovery partnership with Eli Lilly to enhance its pipeline.
Aktis Oncology’s IPO Overview
- Raised $318 million in the first biotech IPO of 2026.
- Focused on developing miniprotein radioconjugates for cancer treatment.
Innovation & Pipeline
- Miniprotein radioconjugates may offer advantages over conventional targeted radiation therapies.
- Collaboration with Eli Lilly enhances discovery potential.
Industry Implications
- Radiopharmaceuticals are gaining traction as a precision oncology approach.
- Aktis’s IPO reflects increased investor interest in next-generation cancer therapies.
Join the BioIntel newsletter
Get curated biotech intelligence across AI, industry, innovation, investment, medtech, and policy—delivered to your inbox.